| Jillian Anne Edmunds, DO | |
|
100 Hitchcock Way, Manchester, NH 03104-4125 | |
| (603) 695-2600 | |
| Not Available |
| Full Name | Jillian Anne Edmunds |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 100 Hitchcock Way, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053755009 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 19453 (New Hampshire) | Secondary |
| 207R00000X | Internal Medicine | 284560 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
CQ HealthBeat reports that Richard Gilfillan, a former head of the Geisinger Health Plan in Pennsylvania, will run the Center for Medicare and Medicaid Services Innovation Center that was created by the health law. Gilfillan was chosen Monday. At Geisinger, Gilfillan ran a plan that "many health policy analysts see as a national model for delivering quality, affordable care" (Reichard, 9/27).
EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.
› Verified 5 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
CQ HealthBeat reports that Richard Gilfillan, a former head of the Geisinger Health Plan in Pennsylvania, will run the Center for Medicare and Medicaid Services Innovation Center that was created by the health law. Gilfillan was chosen Monday. At Geisinger, Gilfillan ran a plan that "many health policy analysts see as a national model for delivering quality, affordable care" (Reichard, 9/27).
EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.
› Verified 5 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
CQ HealthBeat reports that Richard Gilfillan, a former head of the Geisinger Health Plan in Pennsylvania, will run the Center for Medicare and Medicaid Services Innovation Center that was created by the health law. Gilfillan was chosen Monday. At Geisinger, Gilfillan ran a plan that "many health policy analysts see as a national model for delivering quality, affordable care" (Reichard, 9/27).
EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.
› Verified 5 days ago
| Entity Name | Alliance Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891859419 PECOS PAC ID: 8022019215 Enrollment ID: O20070131000394 |
News Archive
CQ HealthBeat reports that Richard Gilfillan, a former head of the Geisinger Health Plan in Pennsylvania, will run the Center for Medicare and Medicaid Services Innovation Center that was created by the health law. Gilfillan was chosen Monday. At Geisinger, Gilfillan ran a plan that "many health policy analysts see as a national model for delivering quality, affordable care" (Reichard, 9/27).
EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jillian Anne Edmunds, DO 100 Hitchcock Way, Manchester, NH 03104-4125 Ph: (603) 695-2600 | Jillian Anne Edmunds, DO 100 Hitchcock Way, Manchester, NH 03104-4125 Ph: (603) 695-2600 |
News Archive
CQ HealthBeat reports that Richard Gilfillan, a former head of the Geisinger Health Plan in Pennsylvania, will run the Center for Medicare and Medicaid Services Innovation Center that was created by the health law. Gilfillan was chosen Monday. At Geisinger, Gilfillan ran a plan that "many health policy analysts see as a national model for delivering quality, affordable care" (Reichard, 9/27).
EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.
› Verified 5 days ago
Jenny Lin, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Dr. Douglas F. Marks Jr., M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 87 Mcgregor St, Ste 4100, Manchester, NH 03102 Phone: 603-695-2500 Fax: 603-695-2647 | |
Dr. Jose E. Lozano, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 718 Smyth Rd, Manchester Va, Manchester, NH 03104 Phone: 603-624-4366 | |
Frances Jensen, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 456 Union St, Manchester, NH 03103 Phone: 866-679-0381 | |
Dr. Victor Gordan, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 718 Smyth Rd, Manchester, NH 03104 Phone: 603-624-4366 Fax: 603-626-6559 | |
Dr. Peter Wilson Shaw, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Mcgregor St # Stb, Manchester, NH 03102 Phone: 603-663-6350 | |
Dr. Goran Broketa, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 718 Smyth Rd, Manchester, NH 03104 Phone: 603-624-4366 Fax: 603-629-3217 |